The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of the KRAS/EGFR mutation profile and survival of “collegiate smokers” and never smokers with advanced lung cancers.
Anna M. Varghese
No relevant relationships to disclose
Camelia S. Sima
No relevant relationships to disclose
Jamie E. Chaft
No relevant relationships to disclose
Melissa Lynne Johnson
Consultant or Advisory Role - Genentech
Research Funding - Novartis
Yelena Yuriy Janjigian
Research Funding - Boehringer Ingelheim
Alexander Edward Dela Cruz Drilon
No relevant relationships to disclose
Helena Alexandra Yu
No relevant relationships to disclose
Gregory J. Riely
Consultant or Advisory Role - Abbott Molecular; ARIAD; Chugai Pharma; Daiichi Sankyo; Novartis; Tragara Pharmaceuticals
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Infinity; Merck; Novartis; Pfizer
Marc Ladanyi
No relevant relationships to disclose
Mark G. Kris
No relevant relationships to disclose